Schaeffer's Top Stock Picks for '25

CarMax, FedEx Head In Opposite Directions After Earnings Beats

FedEx is trading lower, despite a handful of price-target hikes and solid earnings guidance

Managing Editor
Jun 21, 2017 at 10:27 AM
facebook X logo linkedin


U.S. stocks are bouncing back, as stabilizing oil prices are helping markets recover. Among specific names on the move today are used car stock CarMax, Inc (NYSE:KMX), delivery specialist FedEx Corporation (NYSE:FDX), and biotech Cara Therapeutics Inc (NASDAQ:CARA). Here's a quick look at what's moving shares of KMX, FDX, and CARA.

Upbeat Earnings Jump-Start CarMax Stock

CarMax stock is up 7% to trade at $62.80, after the used car company reported earnings per share of $1.13, beating consensus estimates of $0.98. It's been a hectic year for KMX stock, which hit an 18-month high of $69.11 on Feb 16, but has since backpedaled to a year-to-date loss of 2.5%.

Checking the stock's sentiment backdrop, it looks like short-covering activity could be fueling today's early post-earnings gains. Short interest accounts for 16.4% of KMX's float, or nearly 11 times the stock's average daily trading volume.

Solid Earnings, Price-Target Hikes Can't Boost FedEx Stock

FedEx stock is down 1.5% to trade at $206.21, despite an earnings report that beat analyst projections. In addition, FedEx received price target hikes from Deutsche Bank, BMO, Credit Suisse, and Baird. It's been a strong year for the delivery specialist, with FDX stock up 11% year-to-date, and having just reached a record high of $211.88 on June 16.

Today's lackluster reaction in FDX shares could be the result of overly upbeat expectations, judging by rampant bullish speculation in the weeks leading up to the FedEx earnings report. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows FDX stock with a 50-day call/put volume ratio of 1.16, which ranks in the 98th annual percentile.

Cara Therapeutics Stock Gains on Drug Trial Update

Cara Therapeutics stock is up 2.2% today at $18.05, after completing an interim assessment of its phase 3 trial of Cr845 for postoperative pain. It's been a banner year for CARA, which is up 94% year-to-date. The stock has pulled back from its 18-month high of $20.90, tagged on March 29, but CARA has lately found support at its 80-day moving average.

However, there still seems to be a large bearish contingent betting against Cara shares. Over 7 million shares are sold short, accounting for nearly 31% of the stock's total available float.

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter